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Recent revolutionary advances at the intersection of medicine, omics, data sciences, computing, epidemiology, and related technologies inspire us to
ponder their impact on health. Their potential impact is particularly germane to the biology of pregnancy and perinatal medicine, where limited
improvement in health outcomes for women and children has remained a global challenge.We assembled a group of experts to establish a Pregnancy
Think Tank to discuss a broad spectrumofmajor gestational disorders and adverse pregnancy outcomes that affectmaternal-infant lifelong health and
should serve as targets for leveraging the many recent advances. This report reflects avenues for future effects that hold great potential in 3 major
areas: developmental genomics, including the application of methodologies designed to bridge genotypes, physiology, and diseases, addressing
vexing questions in early human development; gestational physiology, from immune tolerance to growth and the timing of parturition; and personalized
and population medicine, focusing on amalgamating health record data and deep phenotypes to create broad knowledge that can be integrated into
healthcare systems and drive discovery to address pregnancy-related disease and promote general health.Wepropose a series of questions reflecting
development, systems biology, diseases, clinical approaches and tools, and population health, and a call for scientific action. Clearly, transdisciplinary
sciencemust advance and accelerate to address adverse pregnancy outcomes. Disciplines not traditionally involved in the reproductive sciences, such
as computer science, engineering, mathematics, and pharmacology, should be engaged at the study design phase to optimize the information
gathered and to identify and further evaluate potentially actionable therapeutic targets. Information sources should include noninvasive personalized
sensors andmonitors, alongside instructive “liquid biopsies” for noninvasive pregnancy assessment. Future research should also address the diversity
of human cohorts in terms of geography, racial and ethnic distributions, and social and health disparities. Modern technologies, for both data-
gathering and data-analyzing, make this possible at a scale that was previously unachievable. Finally, the psychosocial and economic environ-
ment in which pregnancy takes place must be considered to promote the health and wellness of communities worldwide.
Key words: adverse outcomes, artificial intelligence, birthweight, computational biology, developmental origins of adult disease, disparities, drug
discovery, evolutionary biology, fetal growth, fetal growth restriction, genomics, gestational diabetes mellitus, immune tolerance, maternal health,
metabolomics, multiomics, parturition, physiology, population health, precision medicine, preeclampsia, pregnancy, preterm birth, stillbirth
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M ajor adverse pregnancy-specificcomplications—preterm birth,
preeclampsia, fetal growth restriction,
and stillbirth—remain leading causes of
maternal, fetal, and neonatal morbidity
and mortality and are associated with
increased disease risk across the lifespan.1
Despite growing attention, much greater
progress is needed in revealing mecha-
nisms and pathogenic pathways,
advancing clinical diagnostic and thera-
peutic tools, and designing preventive
strategies to push the field forward into
the 22nd century. Modern technologies
such as next-generation sequencing,
artificial intelligence, machine learning,
electronic medical records, and noninva-
sive imaging, data capture and
biochemistries, and contemporary con-
ceptual approaches nowposition thisfield
to accelerate efforts in understanding and
optimizing pregnancy, reaping the asso-
ciated benefits for lifelong health.
To better explore and propose potential
avenues to capitalize on new concepts and
technologies, the Burroughs Wellcome
Fund (BWF) supported a Pregnancy
Think Tank meeting on November 19 to
20, 2019, inResearchTriangle Park,North
Carolina (See Box for description of
BWF). The Think Tankmeeting centered
on generating novel ideas and stimulating
new research opportunities for bolstering
knowledge in the area of pregnancy and
mechanisms underlying pregnancy com-
plications.Weweremotivated by the joint
biennial meetings that were convened by
theBWFand theMarchofDimes, starting
in 2008 under the title “Preventing Pre-
maturity: Establishing a Network for
InnovationandDiscovery,”2 andby recent
initiatives such as the Magee-Womens
Research Institute Summit. Considering
the effect of those meetings on recent
advances in basic, translational, clinical,
and epidemiologic research and the ad-
vances that have emerged overall, the
outlook for thefield has expanded beyond
the vision of BWF’s earlier Preterm Birth
focus to include broader gestational con-
ditions and their effect on lifelong
maternal and infant health.
Our event aimed to assess how
convening experts from divergent
biomedical disciplines, with many sci-
entists from outside the field of
pregnancy research, might foster pro-
ductive and convergent thinking and
generate novel ideas to stimulate inno-
vative research projects. Together, 30
participants from the United States,
Canada, and United Kingdom encom-
passed biological disciplines (Table 1).
Our event was also designed to reshape
the BWF strategy to accelerate discovery,
encouraging proposals that incorporate
new tools, analytic approaches, and sci-
entific disciplines. This summary en-
capsulates the ideas and discussions
organized by broad categories that span
the contributions by experts in the fields
(Table 1) and illuminate advances in
ideas, technology, and talent to have the
greatest potential: developmental geno-
mics, physiology, and personalized and
population medicine. We generated
suggested questions and a call for scien-
tific action, delineating next-generation
challenges and opportunities in the sci-
ence underlying pregnancy and human
early development.
Developmental genomics
The field of developmental genomics
applies state-of-the-art methodologies
that strive to assist in bridging geno-
types, physiology, and disease specifically
to developmental processes from
embryogenesis to parturition biology.
From identification of genetic variants
through sequencing or genome-wide
association studies (GWAS) to defining
nucleotide changes and investigating
their downstream proteomic, metab-
olomic, and physiological consequences
that may play an etiologic role in
phenotypic consequences during preg-
nancy, numerous interrelated steps are
logically aligned to chart the molecular
maps underlying diseases3 (Figure 1).
Pregnancy phenotypes are shaped by the
maternal, fetal, and placental genomes
and epigenomes, and therefore, the
genomic studies of these phenotypes
would benefit from an integrative
approach in mother-infant pairs.
Furthermore, these maps are not two-
dimensional, but include regulatory el-
ements that form three-dimensional
DNA loop configurations to influence
more than 1 proximal or distal gene.4
Notably, gene-regulatory elements
comprise modular arrays of binding sites
for transcription factors whose expres-
sion is context and time specific,
changing across interacting maternal-
fetal tissues and during gestational ages.
These are further modified by environ-
ment-, diet-, or disease-induced epige-
netic changes whose characterization
and transmission are increasingly well
understood.5,6 Generalizing these
genomic processes across populations
and ethnic groups can be accomplished
with large databases and biospecimen
banks with machine learning tools to
probe them, guided, wherever possible,
by biological reasoning and hypothesis
formulation. To date, for most DNA
sequence variants identified, relatively
little mechanistic and actionable data
have emerged. As associations now exist
for preterm birth and birthweight, these
should drive functional studies to
translate the findings to improvements
in clinical care.3,7 These functional
studies should first indicate conclusive
evidence for the actual genes responsible
for the association because the nearest
gene is not always the one relevant for
the phenotype being investigated.8 Sub-
sequent investigations to determine the
mechanism of action of the causal
polymorphism can be performed
in vitro, in cell lines, and now in vivo
using gene-editing technologies. These
approaches determine when and how
during pregnancy the variants modulate
pregnancy outcomes.
Incorporating evolution in pregnancy
By viewing the genesis of pregnancy
through an evolutionary biology lens,
significant insights have been gained, for
example, into the signals required to
maintain the long gestations that many
mammals display. One recent elegant
study by Griffith9 and colleagues found
that by studying marsupial pregnancy the
implantation reaction of eutherians
(formerly “placentals”) derives from the
attachment reaction in ancestral therian
mammals (encompasses both eutherians
and marsupials). In marsupials such as
the opossum, this event leads to prompt
parturition. The ability to shift from the
inflammatory attachment reaction to a
prolonged noninflammatory period in
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gestation is a central innovation in
eutherian mammals that allowed an
extended period of intimate placentation.
Although inferences based on evolu-
tionary biology are powerful in mapping
regulatory elements and traits at the
organism-level, the rapid evolutionary
changes in relevant organs, such as the
placenta,10 may benefit from system-
specific and well-thought-out machine
learning approaches to link genomes to
phenomes. Although the genomic roots
of maternal-fetal tolerance and exchange
are ancient, dating back to reptiles, fish,
and velvet worms, at term only a small
fraction of genes represent the core
placental transcriptome that is conserved
across mammalian or marsupial spe-
cies.11Moreover, eutherian andmarsupial
mammals have evolved imprinting (away
of generating monoallelic expression) as
an additional mechanism to tune gene
expression in a manner informed by
parent of origin. It is possible that phar-
macologically induced diseases in model
organisms, such as the stimulation of
preterm birth in mice, might not be as
revealing as naturally arising variations in
the timing of birth. In this instance, a
mouse strain that evolved to spontane-
ously deliver its pups 3 days earlymight be
more informative. This approach has
been utilized in genetically inbred mouse
strains to determine genetic contributors
to gestational duration and also the co-
ordination of gestational duration with
rates of organ maturation.12,13 Impor-
tantly, the divergent strategies between
species to optimize reproductive out-
comes may in themselves prove infor-
mative for greater mechanistic insights
BOX
About the Burroughs Wellcome Fund
The Burroughs Wellcome Fund (BWF) was established in the United States in 1955 on the legacy of Silas Burroughs and Henry Wellcome,
two American-born colleagues who founded the Burroughs Wellcome Co. in London in the 1880s. The pharmaceutical company flourished
through the 20th Century establishing entities around the globe.
The Fund was the philanthropic arm of the North American branch of the pharmaceutical company. By the time of its creation, the
corporation was run by the Wellcome Trust, a nonprofit entity created by the corporate shares of the global companies. In 1993, the
Burroughs Wellcome Fund was the beneficiary of a $400 million gift from the Wellcome Trust. This endowment allowed BWF to become a
completely independent foundation, with no direct ties to its founding company.
The Reproductive Sciences have been a long-standing focus of BWF as being a critical yet underfunded, undervalued area of research.
BWF history in this domain includes support for American Association of Obstetricians and Gynecologists Foundation (1997-2003), the
Reproductive Scientist Development Program (1998 e present with the NIH), Frontiers in Reproduction, Marine Biological Laboratories
Summer Course (1998 e present), and the Preterm Birth Research Consortium and the Preterm Birth Initiative (2007e 2020) to initially
support meetings and then fund discovery grants around preterm birth. This Think-Tank was the evolution of these initiatives to determine
productive paths for the future discovery.
BWF remains an independent private foundation whose mission is to advance the medical sciences by supporting research and other
scientific and educational activities. BWF focus is on early stage biomedical scientists, particularly physician scientists, along with areas of
investigation that are undervalued or underfunded by other organizations.
George Hitchings, Ph.D., a Nobel laureate who spent most of his career with Burroughs Wellcome Co., served as BWF’s president from
1974 until 1990, and his vision promoted the Fund’s belief in the critical link of basic research and clinical applications in medicine. BWF is
governed by a Board of Directors consisting of accomplished scientists and administrators, with many distinguished advisory committee
members for its competitive award programs. These include HHMI Investigators, National Academies Members, and Nobel Laureates.
For more information on the history of the Burroughs Wellcome Fund please see: https://www.bwfund.org/history.
TABLE 1
Disciplines represented
Anatomy Immunology
Bioengineering Machine learning and artificial intelligence
Chronobiology Microbiome and microbiology
Developmental biology Obstetrics
Drug and device development Pathology
Endocrinology Pediatrics
Epidemiology Personalized medicine
Evolutionary biology Pharmacology
Genomics Population genetics
Global health Systems biology
Health policy Vascular biology
Imaging sciences
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FIGURE 1
The cycle of discovery to strategies to prevent adverse pregnancy outcomes
Human populations with new technologies and omics platforms, integrated with medical history, social determinants, and environmental data, provide
unparalleled opportunities for precision and population medicine.
AGCT, adenine, guanine, cytosine, thymine; GWAS, genome-wide association study; Rx, prescription; WES, whole exome sequencing; WGS, whole genome sequencing.
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into healthy and complicated
pregnancies.
These challenges are further amplified
by the general paucity in knowledge of
maternal-fetal biology. Better tools such
as next-generation sequencing, single-
cell omics, and high-resolution imaging
could bridge the divide between
commonly used mouse and other
gestational models and human preg-
nancy. The advent of single-cell
sequencing of human placental cells,
other cells at the maternal-fetal interface,
and cells in the placenta of other model
organisms may shed light on shared
processes that might otherwise seem
disparate. For example, single-cell tran-
scriptomics from first-trimester pla-
centas, maternal blood, and decidual
cells identified regulatory interactions
that are critical for immune adaptation
and for placentation and diseases during
pregnancy.14
Gestational physiology
It is now clear that the origins of many
healthy developmental processes or dis-
eases begin in the preconception period
and in early pregnancy. For example,
abnormal placental function may be
rooted in defects of the trophoblastic
shell, which encases the embryo within
the maternal milieu.15 Research into
cellular and organismal physiology has
dramatically advanced in the past
decade. GWAS and next-generation
sequencing studies, single-cell omics,
organoids, functional biochemical im-
aging, and other new technologies usher
in ways to interrogate gestational physi-
ology and major obstetrical
syndromes.14,16e19 During the critical
phase of organogenesis across the first 8
to 10 weeks of human gestation, the
endometrial glands supply secretions
(commonly termed “uterine milk”) that
support the developing embryo and are
involved in placental development dur-
ing the first trimester of pregnancy and
spiral artery remodeling. A recently
introduced hormone-responsive endo-
metrial organoid model may shed light
on this early histotrophic support to the
embryo.20 Organoids, by generating a
three-dimensional tissue construct
in vitro from differentiating stem cells,
may more faithfully reflect in vivo
cellular function as related to the organ
or tissue they model than traditional
two-dimensional cultures of trans-
formed or primary tissue culture cells.
Transcriptional profiling of the
endometrial organoid cells indicated
the strong similarity between orga-
noids and the primary originating
tissue. Furthermore, with exposure to
pregnancy signals, endometrial orga-
noids develop characteristics of early
pregnancy and can be more faithfully
used to model early gestational
events. Although the precise compo-
sition of the endometrial gland se-
cretions and their effects on placental
development and organogenesis
remain to be defined, the data suggest
that premature onset of maternal
blood flow into the placenta and
transition from histotrophic to
hemotrophic embryonic support is
associated with early miscarriages.
Could early gestational disorders
reflect deficiencies in the new
trophoblast-endometrial dialog and
maladaptation to a 3-fold higher ox-
ygen level or to new nutritional
sources?
Is pregnancy an immunologic
paradox?
Despite being an allograft, in a healthy
gestation, the maternal immune system
does not reject the embryo, and preg-
nancy seems to be a precisely calibrated
collaboration between the maternal and
fetal needs, with the trophoblast forming
a boundary between the 2 individual
systems. Maternal T cells and decidual
subsets of natural killer cells could
potentially mediate allo-recognition—
the recognition and response of
maternal immune cells to placental
trophoblast cells.21 Somatic fetal cells are
separated by trophoblast from contact
with the mother; thus, stricto sensu,
“fetal rejection” cannot occur. Tropho-
blast organoids can now be used exper-
imentally to investigate the interactions
occurring between maternal decidual
immune cells and the invading tropho-
blast, thus illuminating these critical
transitions during the early stages of
pregnancy.
Reconsidering fetal growth
Beyond the first trimester, precise
changes in fetal growth represent a
complex physiological process that may
not be well captured by simple growth
curves. Importantly, fetal growth is
saltatory, not steady.22,23 Deciphering
normal fetal growth requires deep un-
derstanding of cell differentiation and
the individual, temporal growth patterns
in response to environmental influences.
These may perturb organ growth tra-
jectories, such as those expressed in
growth plate biology, where cell differ-
entiation defines bone elongation.
Natural selection may favor rapid in-
trauterine growth of the human brain
during fetal development, driving birth
to occur relatively early, either before the
fetal head becomes larger than the pelvic
outlet or owing to maternal metabolic
constraints.24,25 Yet, such acceleration in
birth timing leads to an altricial neonate
in terms of neurodevelopment and the
lack of early independence. The traits
may have influenced endocrine signals
between the fetoplacental unit and the
mother, thus linking fetal maturation
(especially brain development) to 1 of
the triggers for parturition. For example,
although the onset of term labor in most
species is triggered by a steep prepartum
drop in maternal serum progesterone
concentration, the serum abundance of
progesterone in women remains high
throughout pregnancy.26 Nonetheless,
loss of the progesterone block to labor
seems to be a terminal event in the
parturition cascade of all viviparous
species studies to date.27 In human
pregnancy, this is thought to be achieved
by redundant mechanisms that interfere
with or overcome progesterone receptor
signaling in uterine cells, which may be
influenced by systemic or local factors,
such as signals from an overdistended
lower uterine segment.
Pregnancy can be viewed as a physical,
cardiovascular, immunologic, meta-
bolic, physiological, and psychosocial
stress test for the mother whose ho-
meostatic systems are challenged by
placental hormones to mostly favor
uterine quiescence while providing the
fetus with resources needed to complete
its growth and developmental program.
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In the future, gestational age as a surro-
gate for the developmental age of the
fetus may be replaced by a panel of other
biomarkers more reflective of fetal
readiness for being delivered. A
mismatch between the production of
placental hormones and the responses
of maternal organ systems to those
hormones may disrupt maternal ho-
meostasis leading to disease. There-
fore, a detailed chronological map of
the placental-maternal endocrine
landscape during human pregnancy
under different circumstances and in
different environments is a central goal
that is now attainable through recent
advances in omic technologies. Such a
map would illuminate key processes in
normal and adverse pregnancy out-
comes and may identify clinical disease
risk biomarkers.
Integrated personalized and
population medicine
The implementation of personalized
medicine and of population medicine
have become high-priority frameworks,
although they often seem to pull in
opposite directions.28 Personalized or
precision medicine aspires to use geno-
mics and other data-driven methods
such as medical history, environmental
exposures, and social determinants for a
given individual to improve diagnosis
and optimize therapeutic decisions.
These methods often blur the distinction
between proven healthcare and research
and can be costly. In contrast, population
medicine seeks to structure, deliver, and
make cost-effective high-value health-
care that improves the overall health of a
given population. A key goal for medi-
cine is to integrate the 2 approaches to
achieve the best outcome for the largest
number of patients. That integration is
now a realistic goal and should be a high-
priority framework for healthcare
systems, patients, investigators, and
funders. Capturing clinical evaluations
along with deep phenotypes through
data from electronic health records and
integrating findings with genomics, so-
cial determinants, environmental in-
sults, and health behaviors to develop
personal health plans is a realistic
goal.29,30 How do we exploit these
advances to optimize pregnancy and
lifelong health?
One addition to healthcare delivery
today is that while we continue to
emphasize the identification of specific
diseases, there is a parallel proactive,
holistic, and personalized approach to
health, with participatory involvement
from the individual that focuses more
on wellness. Although throughout the
1900s, diseases were viewed as discrete
autonomous entities, in the 2000s,
many diseases are perceived in the
context of baseline biological and ge-
netic risks that interact with environ-
mental factors. Medicine will always
need disease-specific approaches for
purposes such as organizing clinical
management most effectively, control-
ling specific infectious diseases, or
dealing with pandemic threats such as
the coronavirus disease 2019 (COVID-
19) that we are now facing. This
additional focus complements the
disease-specific approach by promoting
health and impeding the progression of
clinical disease. One avenue in realizing
this health goal is an integrated systems
approach to pregnancy.31,32 Network-
based modeling and machine learning
approaches that integrate diverse mul-
tiomic data from both mother and child
and consider their possible interactions
hold great promise. These approaches
also enable the integration of other data
sources that capture social, psychologi-
cal, environmental, and other biological
risk factors. These models may be
informed by polygenic risk scores,33
nongenomic factors, or the integration
of both.When stratified from low to high
risk, they may be included in predictive
algorithms that can indicate level of risk
for a pregnant woman or her fetus for a
particular disease. These models, espe-
cially when informed by an inclusive
approach that incorporates environ-
mental risk, may suggest individualized
pathways to preventive medicine.
Improved pregnancy care should be
paralleled by better approaches to care
during infancy and childhood. Proactive,
personalized models of health delivery
with personal health plans should ideally
promote patient engagement, anticipate
and minimize risks, provide best care
standards, and enable continuous adop-
tion of new technologies as they are
validated. The improved perinatal and
neonatal care of recent decades that has
incorporated new technologies as they
emerge has enabled the survival of many
premature and underweight babies who
are at increased risk for a range of
childhood and late-onset diseases.
However, the challenge of preventing the
diseases themselves remains. Preventive
interventions deployed before birth, such
as the administration of steroids or
magnesium sulfate to mothers in pre-
term labor to reduce the risk of
prematurity-related diseases, are relevant
examples, and we hope that wemay soon
be able to address, using the new tech-
nologies described here, additional pre-
ventive approaches to the hazards to
mothers and babies of perinatal inflam-
mation; infectious agents; toxic, envi-
ronmental, and social factors; and other
contributors to perinatal injury.
Leave no population behind
The development of personalized and
population perinatal medicine should
address the disparities in both informa-
tion and outcomes across human pop-
ulations.34 Predictive models are
ultimately limited by available data,
particularly in the context of racial and
ethnic diversity. The overrepresentation
of individuals of European ancestry in
available genetic and environmental
studies of pregnancy presents a risk that
the deployment of personalized medi-
cine approaches could perpetuate dis-
parities in outcomes for underserved
populations. The study of diverse pop-
ulations (diverse in both genetic and
environmental circumstances) will pro-
vide insights into biology and mecha-
nisms. At the same time, pregnancy
health is an area where disparities are
prominent, and addressing them is a
high priority if we are to improve preg-
nancy outcomes. We will need to take a
population health perspective to fully
embrace the promise of new
technologies.
Central questions to answer
The preceding discussions encompass-
ing omics, physiology, and personalized
Special Report ajog.org
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and population medicine promote their
considerations as powerful new tools
and concepts that can ultimately
improve health and prevent disease
through knowledge of underlying
mechanisms and understanding the ef-
fect of genetics, the environment, social
determinants, medical history, and
health behaviors in pregnancy. Strategies
to implement measures for individuals
and populations that take each of these
factors into account can then be ratio-
nally developed. How can these areas be
taken forward and moved into action?
What will be the questions that will have
to be answered and challenges to be
overcome? Discussions from the
Working Group developed the following
lists.
Development
 What are the mechanisms under-
lying the developmental origins of
later-life health and disease? Are
these transgenerational, and can
the effects be mitigated or
reversed?
 What are the evolutionary implications
of the maternal and fetal genomes in
shaping pregnancy phenotypes and
transgenerational effects?
 Although animal models, particu-
larly the mouse, are pertinent for
some mechanistic studies in vivo,
the extent to which they recapitu-
late various aspects of human
pregnancy is unclear and may be
limited. Can model choices be
optimized for each clinical prob-
lem by harnessing comparative
technologies to inform the precise
extent of shared vs unique features
of pregnancy between humans and
other mammals?
 Can some animal models be further
developed in the future, and should
somemodels be replaced by organoids
or other engineered ex vivo models?
 What are the biological mechanisms
that define the gestational clock and
the developmental clocks and how do
they relate? How can these mecha-
nisms be controlled?
 How can endometrial function be
assessed and optimized before
pregnancy?
 Can new standards be set for longi-
tudinal studies of pregnancy, starting
before conception or from the first
trimester of pregnancy?
 How can the power of novel imaging
technologies, alongside liquid bi-
opsies of plasma and extracellular
vesicles, to define time-dependent
normal physiology and abnormal
disease trajectories be harnessed?
 Can environmental vicissitudes be
measured directly or with surrogates?
Can they be integrated into the tem-
poral trajectory of human pregnancy
to explore the role of external factors
in birth timing?
Systems biology
 How can powerful, maternal-fetal
multiomic approaches serve to rede-
fine pregnancy health?
 What is the role of single-cell atlases,
mass cytometry, and organoids in
understanding pregnancy-related cell
systems?
 Can a set of interacting organoid tis-
sues capture a more complete system
of gestational biology and be deployed
to study development and even
therapeutics?
 Should “reference” data sets of preg-
nant women and their offspring,
which are large enough to include
confounding factors, be developed
and deidentified and bemade publicly
available for mining?
 Can better interaction with machine
learning labs be stimulated, thus
ensuring that cutting-edge technolo-
gies can be deployed rapidly and that
investigations can better identify and
classify novel variables?
 How do the evolutionary and de-
mographic histories of different hu-
man populations modulate baseline
risk for diseases of pregnancy?
Diseases
 How can understanding of the effect
of racial, ancestral, nutritional, and
environmental differences in the
pathobiology of perinatal diseases be
accelerated?
 What initiates the onset of labor and
the timing of birth, and what causes
premature initiation of such signals?
 What truly defines the differential
contribution of the placenta to major
diseases of pregnancy: implantation
failure and pregnancy loss, fetal
growth restriction, preeclampsia, fetal
death, and preterm birth?
 Can the power of modern technolo-
gies be harnessed to access the
placenta and other intrauterine tis-
sues in real time and throughout
pregnancy and identify deviations
toward disease even before they
manifest clinically?
 Can “natural experiments,” such as
surrogacy, help in understanding the
immune basis of pregnancy loss and
immunologic abnormalities of
pregnancy?
Clinical approaches and tools
 Can health hazards that can be safely
and efficiently removed early in
pregnancy be identified?
 What is the potential to collaborate
with the wearable and sensor industry
in the development of continuous
monitoring systems during preg-
nancy and in alerting physicians
about early deviations from
“normal?”
 Can novel noninvasive tools be
deployed for longitudinal assessment
of pregnancy health?
 Can better involvement of the phar-
maceutical industry be fostered to
improve the safe deployment of new
drugs or the repurposing of existing
drugs during pregnancy?
 Can informatics tools, including
artificial intelligence, be incorporated
into drug discovery strategies?
 What will be the safest and most
informative approaches to determine
kinetics and efficacy of drugs in hu-
man pregnancy to prevent or treat
pregnancy complications?
 What is the optimal path to enhance
our engagement of ethicists in discus-
sions about studies during pregnancy,
particularly pregnancy monitors?
Population health
 Is it possible to translate our basic
science findings into actions that can
producemeasurable improvements of
health at the population levels?
ajog.org Special Report
MONTH 2020 American Journal of Obstetrics& Gynecology 7
 What is the best strategy to examine
naturally occurring variations in
disease risk in pregnancy and the
perinatal period in different pop-
ulations to inform our scientific
agendas?
 How can data arising from many
levels—social, psychological, physio-
logical, metabolic, and genomic—
best be integrated into a real agenda
for improved pregnancy health?
 How can newly arising population
risks for poor pregnancy outcomes
from infectious, environmental, so-
cial, or other changes as early as
possible in their genesis be better
prepared for?
Summary: a call for scientific action
While addressing diverse questions,
Think Tank participants converged on
several themes that cross biomedical
disciplines and research trajectories
(Figure 2). First and foremost, the
transdisciplinary approaches weaved
together by our diverse experts led to
identification of key areas that need
further exploration to advance and
accelerate the solution to the identified
complex challenges. The science under-
lying pregnancy and its translation to
medicine is complicated and multidi-
mensional, requiring the assembly of
distinct expertise, working at many sci-
entific levels and focusing on shared
goals. Such assembly may pave the way
to improve pregnancy health, personal-
ized for the individual and applicable to
the population and drawn up on the
basis of all the data that can be collected
and monitored for and by each patient.
Disciplines not traditionally involved in
the reproductive sciences, such as com-
puter science, engineering, mathematics,
and pharmacology, should be engaged at
the study design phase to optimize the
information gathered and to identify and
further evaluate potentially actionable
therapeutic targets.
There has been an impression that
pregnancy research is not in vogue,
creating an opportunity for new talented
scholars to join the field. Greatly needed
advances in the field will depend on the
next generation of scholars. This should
become a priority for the academic
world. Furthermore, medical schools
should place greater emphasis on
training students to handle new multi-
dimensional information and discuss it
with patients, accommodating to the
way care is poised to be delivered in the
not-so-distant future.
Future research should include
enough participants to span the diversity
of human cohorts in terms of geography,
racial and ethnic distributions, and so-
cial and health disparities. Broad studies
must be introduced on the basis of
ethical principles and regulatory
compliance. To attain larger and more
useful data sets, it may be time to include
more heterogenous data and, thus, better
reflect the “real world” of clinical
practice, offering stronger conclusions.
Bigger, more population-representative
data sets will provide important in-
sights that can be validated in more
controlled settings. Modern technolo-
gies, for both data-gathering and data-
analyzing, make this possible at a scale
that was previously unachievable.
Research in the prepregnancy period
and across the 9 months of pregnancy
may benefit from the introduction of
noninvasive, personalized sensors and
monitors, alongside informative “liquid
biopsies” for noninvasive pregnancy
assessment. These will advance the
application of mechanistic knowledge
into human health and enrich disease-
based and general precision medicine
FIGURE 2
Word cloud of themes emerging from Pregnancy Think Tank discussions
Sadovsky. Pregnancy as a key window for discovery. Am J Obstet Gynecol 2020.
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paradigms. Access to much-needed tis-
sues from early pregnancy can be pro-
moted by broader international
collaborations. Furthermore, the psy-
chosocial and economic environment in
which pregnancy takes place cannot be
ignored.
Overall, real progress in the under-
standing of pregnancy will take not only
integrative science but also more time
and, most importantly, more imagina-
tion. BWF and other funding agencies
should find ways to promote innovation,
not averting from “risk” in approaches.
Academic departments at most
GLOSSARY OF TERMS
Altricial: born in an immature state requiring prolonged care
Artificial intelligence: the computation ability to process data, to learn from data analysis, and to apply and adapt to that learning to attain
goals
Epigenetic: external modifications to DNA or RNA that lead to changes in gene expression without change to the nucleic acid sequence itself
Genome-wide association study (GWAS): a method commonly used in genetics to identify associations between common genetic variations
occurring in populations with specific disease or traits
Genomics: the study of the structure, function, and evolution of genomes
Gene-regulatory elements: genome components that modulate transcriptional and posttranscriptional activity of genes. Examples include
promoters and enhancers that are cis-acting DNA sequences, most often in noncoding regions of DNA that regulate transcription.
Hemotrophic: the transfer of blood-borne materials between the maternal and fetal circulations for nutrition of the fetus
Histotrophic: the use of extracellular material derived from the endometrium and the uterine glands that accumulates in the space between
the maternal and fetal tissues for nutrition
Machine learning: the use of computational algorithms and statistical models that perform analyses without specific instructions
Mechanisms: the fundamental processes responsible for a specified action, phenotype, trait, or other natural phenomenon
Metabolome: the composition of the entire set of metabolites present within an organism or one of its compartments
Microbiome: microorganisms and their genes that populate a specific environment
Organoid: three-dimensional tissue constructs that are derived from stem cells in vitro that mimic the corresponding in vivo organ
Personalized medicine: healthcare individualized by a person’s unique genetic, environmental, and social characteristics
Phenome: the set of all phenotypes expressed by a biological compartment such as a cell, tissue, organ, or organism
Population medicine: clinical contributors to health that includes the important function of nonmedical stakeholders (education, social,
business) to have a wider influence
Precocial: born in an advanced state capable of early survival with little support
Proteome: the composition of the entire set of proteins present within an organism or one of its compartments
Transcription factor: proteins that activate or repress genes by binding to DNA
Transcriptome: the composition of the entire set of RNA transcripts present within an organism or one of its compartments
Viviparous: giving rise to live birth from inside the body of the parent
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universities should encourage and foster
innovative, multidimensional, and
transdisciplinary science and its applica-
tion to integrative health and wellness.-
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